Background: Pannexin 1 contains multiple cysteine residues and is highly expressed in cell types rich in nitric oxide species. Results: S-nitrosylation of Pannexin 1 on cysteines 40 and 346 inhibits channel currents and ATP release. Conclusion: Pannexin 1 channel function can be regulated by S-nitrosylation. Significance: Our results provide the first evidence of a reversible post-translational modification on Pannexin 1 to regulate channel activity.
Pannexin 1 (Panx1) is a widely expressed integral membrane protein that is thought to form hexameric plasma membrane channels (1) . Since their identification in 2000, Panx1 channels have been characterized as ATP release channels that may play a pivotal role in supporting purinergic signaling in a multitude of cell types (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Importantly, Panx1 channels mediate ATP release from vascular smooth muscle and endothelial cells (7, 14) , circulating erythrocytes (11, 15) , airway epithelial cells (13), astrocytes (5, 16, 17) and Tcells (6, 8) . As purinergic signaling events are critically involved in a number of physiological and pathological processes (18-22), elucidation of the mechanisms controlling the activity of Panx1 channels may provide important insight into how these processes are regulated.
Panx1 channel activation is now known to occur in response to membrane stretch and high extracellular K + (23), to activation of α 1D -adrenergic receptors (7), PAR-1 receptors (14) , and NMDA receptors (24), and by cleavage of its intracellular C-tail by activated caspases 3 and 7 (9, 25) . Since sustained ATP release from cells is detrimental to cell viability, it is crucial that the activity of these channels be tightly regulated to prevent depletion of ATP. Even as novel forms of Panx1 channel activation continue to emerge, mechanisms leading to inhibition of these channels remain poorly understood.
Through the initial characterization of Panx1, evidence has arisen indicating that the channel is post-translationally modified by glycosylation at asparagine 254, an event thought to regulate trafficking of Panx1 channels to the plasma membrane (26, 27) . Panx1 channels can also be irreversibly modified during apoptosis by cleavage of the intracellular C-tail by caspases, allowing release of ATP that serves as a "find-me" signal for monocyte recruitment and phagocytosis (9, 25) . Whereas recognition of these post-translational modifications has provided critical insight into the regulation of Panx1 trafficking and the role of Panx1 in apoptosis, there are currently no known reversible post-translational modifications involved in the regulation of Panx1 channel activity at the plasma membrane.
Protein S-nitrosylation is a reversible posttranslational modification in which nitric oxide (NO) moieties are covalently bound to reactive cysteine thiols via an S-nitrosothiol bond. Snitrosylation can have profound effects on protein function with modification of even a single cysteine residue dramatically altering protein activity (28, 29) . This modification is known to regulate the activity of several membrane channels including, among others, connexin43 (Cx43) gap junctions and hemichannels (28,30), the cardiac slowly activating delayed rectifier potassium channel KCNQ1 (31), the transient receptor potential channel TRPC5 (32) and the ryanodine receptor type 1 (29). Notably, Cx43, a constituent of gap junction channels with a similar membrane topology and oligomerization state as Panx1, is modified by S-nitrosylation at a single cysteine residue in small arteries leading to an increase in channel permeability to second messengers (28).
Panx1 contains several cysteine residues that may play important roles in the regulation of channel function. As Panx1 is highly expressed in tissues rich in NO, such as the vasculature and nervous system, we sought to determine if Panx1 can be post-translationally modified by Snitrosylation and whether this modification can affect channel activity. ________________________________________
EXPERIMENTAL PROCEDURES
Chemicals and reagents -Reduced Lglutathione (GSH), DL-Dithiothreitol (DTT), Nethylmaleimide (NEM) and 1H- [1, 2, 4] Oxadiazolo [4,3-a] quinoxalin-1-one (ODQ) were purchased from Sigma. Diethylammonium (Z)-1-1(N, N-diethylamino)diazen-1-ium-1,2-diolate (DEA-NONOate) was purchased from Cayman chemicals and prepared by dissolving in 10 mM NaOH (all DEA solutions were adjusted to pH 7.4).
S-nitrosoglutathione (GSNO) was prepared by incubating reduced GSH with sodium nitrate. Carbenoxolone (CBX) was purchased from Fisher. Biotin-HPDP and EZ-link sulfo-NHS-LCbiotin were purchased from Thermo Scientific.
Cell culture and transfections -Human embryonic kidney (HEK) 293T cells were cultured in Dulbecco's modified eagle medium (DMEM) High Glucose (Gibco) supplemented with 10% fetal bovine serum (Life Technologies), 1% penicillin/streptomycin, 1% L-glutamine and 1% non-essential amino acids and maintained at 37°C in a humidified 5% CO 2 incubator. All cells were used for experiments at passage ≤ 20. Primary mouse aortic endothelial cells (mAECs) were purchased from Cell Biologics, cultured in ECM-MV media and maintained at 37°C in a humidified 5% CO 2 incubator. All mAECs were used for experiments at passage ≤ 8 as per the manufacturer's recommendations.
Cells at 80-90% confluency were transfected with plasmids or siRNAs using the Lipofectamine 2000 reagent (Invitrogen) following the manufacturers protocol. For electrophysiology experiments, cells were co-transfected with the Panx1 pcDNA3.1 plasmid and green fluorescent protein (2.5 µg of Panx1 plasmid with 0.5 µg of pEGFP) and plated onto poly-L-lysine-coated glass coverslips 24 hours later. The cells were returned to the incubator and allowed to adhere for at least 1 hour prior to use. Recordings were conducted within 1 day of plating.
Plasmid generation and site-directed mutagenesis -Full length murine Panx1 coding region was amplified by PCR from a Panx1-EGFP-N1 plasmid, previously described in (33), using the following primers: forward -5'caaatgggcggtaggcgtgt 3', reverse -5' cttgtggccgtttacgtcgc 3'. The PCR product was digested (HindIII and BamHI) and ligated into pcDNA3.1. The final construct was sequenced to confirm proper insertion. Single cysteine-toalanine mutations were performed in the Panx1 pcDNA3.1 construct using the QuikChangeII SiteDirected Mutagenesis Kit (Agilent Technologies) and double cysteine-to-alanine mutations were constructed using the QuikChange Multi SiteDirected Mutagenesis Kit (Agilent Technologies) following the manufacturer's protocol.
Biotin Switch assay -The biotin switch assay was performed as previously described (28,34). Briefly, cell monolayers were treated with 100 µM GSNO, 50 µM DEA-NONOate or vehicle for 10 minutes at 37°C. Monolayers were then washed with PBS, cells lysed in RIPA buffer containing protease inhibitors and protein quantified using the Bradford technique. Proteins were precipitated with acetone and pelleted by centrifugation for 5 minutes at 10,000xg. Pellets were resuspended and free cysteine thiols were blocked with NEM for 20 minutes at 50°C. Proteins were precipitated as described above to remove excess NEM and Snitrosylated cysteines were reduced with 1 mM ascorbate in the presence of 1mM Cu 2+ and biotinylated with biotin-HPDP for 1 hour at room temperature. Biotinylated proteins were then pulled down with streptavidin-agarose beads for 1 hour at room temperature and subjected to SDS PAGE and Western blotting for detection of Snitrosylated Panx1.
For negative controls, ascorbate was omitted from the assay which prevented reduction of S-nitrosothiols and subsequent biotinylation.
Electrophysiology -Whole cell voltage-clamp recordings were performed as described (25). Recordings were obtained at room temperature with 3-5 MΩ Sylgard-coated borosilicate glass patch pipettes and an Axopatch 200B amplifier (Molecular Devices).
The internal solution contained 30 mM tetraethylammonium chloride, 100 mM CsMeSO 4 , 4 mM NaCl, 1 mM MgCl 2 , 0.5 mM CaCl 2 , 10 mM HEPES, 10 mM EGTA, 3 mM ATP-Mg and 0.3 mM GTP-Tris (pH 7.3). The bath solution was composed of 140 mM NaCl, 3 mM KCl, 2 mM MgCl 2 , 2 mM CaCl 2 , 10 mM HEPES and 10 mM glucose (pH 7.3). Bath solutions containing 50 µM CBX, 1 mM DTT, or 100 µM DEA NONOate (bubbled with 100% O 2 ) were flowed over the cells at a rate of approximately 2 ml/min while 100 µM GSNO, 100 µM GSH, or 100 µM GSH with 100 µM H 2 O 2 were pipetted directly into the bath under stopflow conditions. Ramp voltage clamp commands were applied at 5-s intervals using pCLAMP software and a Digidata 1322A digitizer (Molecular Devices). Peak currents were taken at +80 mV and percent inhibition was calculated by dividing the decrease in peak current by the total Panx1 current (defined by its CBX sensitivity). We quantified the DTT-reversible component of GSNO/DEA-inhibited current to define the fraction of current inhibition that was due to Snitrosylation.
ATP release assay -HEK293T cells or mAECs were plated in 24 well plates coated with 0.01% poly-L-lysine or 0.2% gelatin, respectively. HEK293T cells at 80-90% confluency were transfected with plasmids encoding Panx1 WT or Panx1 cysteine mutants for 24 hours. mAECs, cells were either allowed to grow to confluency or transfected at 80-90% confluency with two siRNAs targeting Panx1 (Ambion)(7) for 48 hours to knockdown endogenous Panx1. The media was removed from each well and cells were carefully washed 2 times with warm Krebs-HEPES buffer containing 2 mM Ca 2+ and 1%
BSA. Cells were then incubated in fresh Krebs-HEPES buffer containing 2 mM Ca 2+ and 1% BSA for 30 minutes at 37°C to allow degradation of any ATP released as a result of mechanical stimulation imparted by changing the media.
Ectonucleotidases were inhibited by incubating cell monolayers with 300 µM ARL 67156 (Tocris) for 30 minutes at 37°C.
HEK293T cells were stimulated by depolarizing the cells with 100 mM KCl for 1 minute or from mAECs by treatment with 1 U/mL mouse thrombin for 5 minutes (as previously described (14)). To evaluate the effect of NO donors on ATP release, cells were pretreated with 100 µM GSNO or 50 µM DEA NONOate for 10 minutes. For controls, cells were pretreated with 100 µM GSH or 50 µM CBX. Following stimulation of the cells, 75 µL of the cell supernatant was collected and placed immediately on ice. All samples were centrifuged at 5000xg for 2 minutes and 50 µL of each sample was transferred to a 96-well plate. Using a FluoStar Omega luminometer, 50 µL of luciferin:luciferase reagent (ATP bioluminescence assay kit HSII; Roche) was injected into each well and luminescence was immediately recorded. ATP concentration in each sample was calculated from a standard curve for all experiments. Data are expressed as a % change in ATP release from control conditions (i.e., unstimulated cells) or % inhibition of ATP release by GSNO for experiments on HEK293T cells expressing Panx1 cysteine mutants.
Cell surface protein biotinylation -HEK293T cells were transfected to express Panx1 WT or Panx1 cysteine mutants as described above and grown to confluency in 6-well plates.
For experiments examining the effect of NO donors on Panx1 membrane expression, confluent monolayers were treated for various times (0-10 minutes) with GSNO. Cells were washed once with cold PBS then incubated with cold DMEM (without FBS) and 50 µM CBX at 4°C for 30 minutes. CBX was added to prevent biotin from passing through Panx1 channels, which would label intracellular proteins.
Cells were then washed with PBS and incubated at 4°C for 1 hour in cold PBS (1.5 mL/dish) containing EZ-linksulfo-NHS-LC-biotin (1 mg/mL) and CBX (50 µM). The cells were washed again with PBS and lysed in PBST (PBS + 0.5-1% Triton-X 100) containing protease inhibitors. Total protein was quantified using the Bradford technique and equal amounts of protein were incubated with Streptavidin-agarose beads for 2 hours at 4°C to pull down biotinylated proteins. Beads were washed 5 times with PBST, spun down and bound proteins eluted by incubation with laemmli buffer. Eluted proteins were subjected to SDS-PAGE and Western blotting for detection of Panx1.
Immunofluorescence microscopy -Transfected HEK cells were fixed in 4% PFA for 15 minutes and subjected to standard immunocytochemistry as previously described (7). Images were obtained with an Olympus Fluoview 1000 laser scanning confocal microscope.
cGMP assay -Transfected HEK cells were incubated with ODQ (10 µM) for 20 minutes prior to treatment with GSNO (100 µM) or vehicle for 10 minutes at 37°C. Cells were then isolated and lysed in buffer provided in the cGMP XP® Assay kit (Cell Signaling) and the assay was performed according to manufacturer's protocol. A standard curve of known cGMP concentrations was constructed and used to calculate cGMP concentrations in the experimental samples.
Data Analysis -Results are presented as means ± SEM.
Statistical significance was determined by p < 0.05 using a Mann-Whitney Utest or Kruskal-Wallis test followed by Dunn's test for multiple comparisons.
RESULTS

Panx1 can be S-nitrosylated.
To determine if Panx1 can be S-nitrosylated, we transfected HEK293T cells with a plasmid encoding murine Panx1 and treated the cells with two independent NO donors: S-nitrosoglutathione (GSNO) or diethylamine NONOate (DEA NONOate). This provides a useful model system for examination of Panx1 modifications since we find that endogenous Panx1 is undetectable in these cells (35). In addition, Western blot analysis did not reveal expression of any nitric oxide synthase (NOS) isoforms in these cells (data not shown), providing a clean model system with little to no background NO from endogenous sources.
Application of 100 µM GSNO or 50 µM DEA NONOate for 10 minutes induced S-nitrosylation of Panx1 as detected by the biotin switch assay (Fig. 1 ). Treating cells with a reducing agent (DTT, 1 mM) immediately following GSNO or DEA NONOate treatment to reduce Snitrosothiols prevented biotinylation in this assay. In addition, S-nitrosylation of Panx1 was not observed in untransfected cells or when the ascorbate step was omitted to prevent unmasking of S-nitrosylated cysteines for subsequent biotinylation. The biotin switch assay can detect proteins with cysteine modifications in addition to S-nitrosylation, and GSNO is capable of also modifying cysteine thiols by S-glutathionylation. Therefore, we treated Panx1
WT expressing HEK cells with reduced glutathione (GSH, 100 µM). Importantly, we did not observe Panx1 modification by GSH in these cells (Fig 1A) . Protein S-glutathionylation occurs more readily under conditions of oxidative stress, but we did not observe any Panx1 cysteine modification when Panx1
WT expressing cells were exposed to reduced GSH in the presence of 100 µM H 2 O 2 . This further supports a role for Panx1 S-nitrosylation over S-glutathionylation (Fig 1B) . Taken together, these results indicate that Panx1 can be Snitrosylated.
S-nitrosylation inhibits Panx1 channel function.
To determine the functional consequences of S-nitrosylation on Panx1 channel activity, we examined the effects of GSNO and DEA NONOate on whole cell currents from Panx1 WT expressing HEK cells. The peak current evoked by voltage ramp protocols (at +80 mV) was strongly inhibited by GSNO (Fig 2A and 2B) . Importantly, and as expected for an effect mediated by S-nitrosylation, GSNO-mediated current inhibition was completely reversed by the reducing agent, DTT (Fig 2A and 2B) . The current restored by DTT was inhibited by the Panx1 channel blocker, carbenoxolone (CBX) and displayed a current-voltage relationship characteristic of Panx1 (Fig. 2B) ; note that GSNOmediated inhibition was evident over the entire voltage range, including at rest potentials. We quantified the DTT-reversible component of GSNO-inhibited current, relative to the CBXsensitive current, as a measure of the percentage of Panx1 current that was reduced by S-nitrosylation (~63%, Fig. 2C ). The DTT-reversible inhibition was significantly greater following GSNO treatment, by comparison to that following GSH or GSH with H 2 O 2 application, consistent with the biotin switch data which suggested that the channel was modified by S-nitrosylation rather than S-glutathionylation. We also observed DTTreversible current inhibition following application of DEA NONOate (data not shown). However, the response with DEA NONOate was less consistent than with GSNO (n=2 of 6 cells tested), and effects of the compound were not more evident when applied at higher concentrations (up to 1 mM) or at elevated temperature (30°C). There was no significant activation of current by DTT in Panx1-expressing cells that had not been treated with NO donors, and there were no detectable CBX-sensitive currents in untransfected cells (data not shown).
In addition to S-nitrosylation, increases in NO can activate soluble guanylate cyclase (sGC) and promote downstream cGMP-dependent phosphorylation cascades.
Therefore, we examined whether GSNO treatment activated sGC in our cells and if this contributed to GSNOmediated Panx1 current inhibition. Western blot analysis revealed endogenous expression of sGC in our HEK cells that was not affected by transfection with the murine Panx1 plasmid or by treatment with GSNO (Fig 2D) . While GSNO did not affect the expression of sGC, we observed a significant increase in intracellular cGMP concentration following GSNO treatment in Panx1
WT expressing HEK cells that could be blocked by pretreatment with the sGC inhibitor ODQ (Fig 2E) . To rule out the possibility that GSNO was exerting its functional effects on Panx1 currents by activation of cGMP-dependent signaling cascades, we pretreated Panx1 WT expressing HEK cells with 20 µM ODQ and examined the effect of GSNO on Panx1 currents. Importantly, ODQ had no effect on Panx1 current inhibition by GNSO (Fig 2F) . Taken together, these data indicate that NO can inhibit Panx1 currents by a mechanism distinct from cGMP signaling, likely by S-nitrosylation of the channel.
While our electrophysiology experiments provide strong evidence that Panx1 channel currents can be inhibited by S-nitrosylation, we also sought to determine if ATP release from Panx1
WT expressing HEK cells is functionally affected by S-nitrosylation. Based on previous reports indicating the ability of Panx1 channels to release ATP in response to high extracellular K WT expressing HEK cells with 100 mM KCl and observed a significant increase in ATP release into the extracellular medium that was strongly inhibited by CBX ( Fig  2G) . There was no change in ATP release from untransfected HEK cells following KCl stimulation, indicating that Panx1 expression was required for ATP release in these cells. Importantly, treatment of Panx1 WT expressing HEK cells with 100 µM GSNO or 50 µM DEA NONOate attenuated the KCl-evoked ATP release, consistent with our observations on the effects of these NO donor molecules on Panx1 channel currents. Moreover, pretreatment with GSH had no effect on ATP release from these cells ( Fig  2G) .
To examine the possibility that the reduction in Panx1 current and ATP release following treatment with our NO donors was due to reduced expression of these channels at the plasma membrane, we performed a membrane biotinylation assay on Panx1
WT expressing HEK cells treated with GSNO for a time course from 0 to 10 minutes, a time frame consistent with the observed inhibitory effects on Panx1 currents. Treatment of cells with GSNO did not affect Panx1 expression at the plasma membrane (Fig.  2H) . Moreover, treatment of Panx1
WT expressing HEK cells with GSNO for 10 minutes had no effect on Panx1 membrane localization as assessed by immunofluorescence microscopy (Fig. 2I) . Together, these data indicate that the inhibitory effect of S-nitrosylation on Panx1 channels is unlikely to reflect decreased plasma membrane expression of the channel.
Multiple cysteine residues contribute to Panx1 current inhibition by S-nitrosylation.
To determine which cysteines are modified by S-nitrosylation and contribute to Panx1 inhibition, we generated several cysteine-to-alanine mutations in Panx1 by site-directed mutagenesis. A topology map of Panx1 indicating the cysteines in which we made alanine substitutions (red circles) is shown in Fig. 3A . We identified target cysteines through a combination of experimental and computational evidence.
Previous studies have reported increased Panx1 channel currents upon mutation of C40 or C346, suggesting that these residues may be intimately involved in channel regulation (29-31). The C-terminal tail, which contains an additional cysteine (C426), may also be important for channel regulation as removal of the C-tail increases channel activity (19). Additionally, we used the scan-x post-translational modification prediction method (36) to rank the highest probability S-nitrosylation sites, which pointed to C40 as the most likely S-nitrosylation site. Therefore, we constructed single cysteine-toalanine substitutions at these sites (Panx1 C40A , Panx1 C346A and Panx1 C426A ). To ensure that mutation of these single cysteines did not affect trafficking to the plasma membrane, we performed immunofluorescence microscopy on mutant expressing cells under nonpermeabilizing conditions with an antibody directed against the second extracellular loop of Panx1 (anti-Panx1 EL) and under permeabilizing conditions with an antibody directed against the intracellular C-tail (anti-Panx1 CT). We found that all Panx1 cysteine mutants were able to reach the plasma membrane (see Fig. 3B and recordings of Cys-substituted channels below). Moreover, we performed cell surface biotinylation assays on HEK cells expressing each of these Panx1 mutants and found that all localize to the membrane and their expression was not affected by treatment with GSNO (Fig. 3C ). In addition, there was no significant difference in Panx1 holding current or basal ATP release between WT and the Panx1 cysteine mutant channels (Fig 3D and Fig 3E,  respectively) .
To determine which cysteine residue(s) are modified by S-nitrosylation, we treated HEK cells expressing Panx1 single mutant channels with 100 µM GSNO and performed biotin switch assays. Interestingly, S-nitrosylation of Panx1 was preserved in all three constructs with individual cysteine-to-alanine substitutions (Fig. 4A) . It should be noted that mutation of C40 or C346 resulted in decreased representation of the higher molecular weight glycosylation species of Panx1 in this assay (Fig. 4A) . Although all three single Cys mutant channels retained the ability to be Snitrosylated, the inhibitory effects of GSNO on Panx1 currents were abolished specifically in Panx1 C40A (Fig. 4B ) and Panx1 C346A (Fig. 4C ) expressing cells; GSNO-mediated inhibition was preserved in Panx1 C426A expressing cells (Fig. 4D ). Summary data for each Panx1 single cysteine mutant is shown in Fig. 4E indicating that mutation of C40 or C346, but not C426, significantly prevented Panx1 current inhibition by GSNO.
Consistent with a lack of current inhibition by GSNO in the Panx1 C40A and Panx1 C346A mutants, ATP release from cells expressing these two Panx1 mutants was not affected by GSNO, with the Panx1 C426A mutant exhibiting strong inhibition (Fig. 4F) . The ability of Panx1 to be S-nitrosylated in each Panx1 single cysteine mutant, with a loss of current inhibition and inhibition of ATP release by GSNO only in the Panx1
C40A and Panx1 C346A mutants, suggested that S-nitrosylation at multiple cysteine residues may be required for channel inhibition.
To determine if multiple cysteines can be Snitrosylated, we generated double cysteine-toalanine substitutions in Panx1 (Panx1 C40/346A , Panx1 C40/426A and Panx1 C346/426A ) and tested the ability of GSNO to S-nitrosylate and inhibit the double mutant channels. Each of the Panx1 double cysteine mutants trafficked to the plasma membrane and expression was unaffected by GSNO (Fig. 3C) . The GSNO-induced Snitrosylation was preserved in Panx1 constructs that retained either C40 or C346, but was lost in Panx1 channels missing both C40 and C346 (Panx1 C40/346A ), indicating that these two cysteines are the sites of modification (Fig. 5A ). All double mutant constructs generated CBX-sensitive Panx1 currents, but GSNO-mediated current inhibition was not observed in any of the double mutant constructs, each of which had a substitution at either C40 or C346 (Fig. 5B-5E ). Consistent with this, GSNO was unable to inhibit ATP release from cells expressing any of the Panx1 double mutant constructs (Fig. 5F ). Together, these data support the idea that both C40 and C346 can be Snitrosylated and modification at both sites is required for GSNO-mediated inhibition of Panx1.
S-nitrosylation of Panx1 in endothelial cells inhibits channel function.
Panx1 is highly expressed in endothelial cells across the arterial tree (35). Because these cells express eNOS and are exposed to large amounts of NO, we sought to determine if Panx1 can be modified by S-nitrosylation in a native cell. We utilized primary cultures of mouse aortic endothelial cells (mAEC) which express eNOS and the endothelial cell markers VE-cadherin (Cdh5) and PECAM-1 (data not shown). Treatment of mAECs with GSNO or DEA NONOate for 10 minutes induced S-nitrosylation of endogenous Panx1 (Fig 6A) . Consistent with our HEK cell data, S-nitrosylation of Panx1 in mAECs by GSNO or DEA NONOate was reversed by treatment with DTT.
Moreover, treatment with GSH alone had no effect on Panx1 cysteine modification.
To determine if S-nitrosylation of Panx1 in mAECs inhibits channel function, we conducted whole-cell patch clamp recordings and ATP release assays on mAECs. Single mAECs were patched in the whole cell configuration and Panx1 currents were identified by their sensitivity to CBX and their characteristic I/V relationship ( Fig  6B-C) . Consistent with our previous observations, peak Panx1 currents at +80 mV were significantly inhibited by GSNO and this inhibition was substantially reversed by treatment with DTT ( Fig.  6B-D) . Treatment with GSH or DTT alone did not affect Panx1 current in these cells indicating that S-nitrosylation of endogenous Panx1 causes potent inhibition of channel currents. We next sought to determine whether ATP release from Panx1 channels in mAECs was affected by Snitrosylation. Because thrombin is a stimulus for ATP release from Panx1 channels in ECs (14), we stimulated mAECs with 1U/mL of thrombin for 5 minutes.
Thrombin stimulation significantly increased ATP release that was inhibited by both CBX and siRNA knockdown of endogenous Panx1 (Fig. 6E) . Moreover, GSNO and DEANONOate significantly attenuated ATP release from mAECs, indicating that S-nitrosylation inhibits endogenous Panx1 channel function, confirming our findings on HEK cells.
DISCUSSION
In this study, we identify a novel inhibitory mechanism for Panx1 channels: we show that Panx1 can be modified by S-nitrosylation and that this post-translation modification leads to inhibition of Panx1-mediated currents and ATP release. In brief, we used a biotin switch assay to show that GSNO and DEA NONOate, two NO donor molecules, induce a DTT-sensitive Panx1 modification that is consistent with Snitrosylation; also, it was not observed when GSH was substituted for GSNO in control or oxidative conditions, ruling out an alternative glutathionylation mechanism. Likewise, inhibition of whole cell Panx1 currents by GSNO and DEA NONOate was reversed by DTT, an action that was also not mimicked by GSH. In addition, GSNO-mediated current inhibition was not dependent on sGC activity, supporting Snitrosylation over other mechanisms that can contribute to NO actions. In support of a direct inhibitory effect on the channel, substitution of either C40 or C346 on Panx1 prevented GSNOmediated channel inhibition, while mutation of both C40 and C346 blocked S-nitrosylation of the channel. In sum, these data demonstrate that modification at these two critical cysteines is required for Panx1 channel inhibition by Snitrosylation, and they suggest a functional role for NO in regulating the activity of Panx1 channels.
The role of Panx1 channels in ATP release from cells has been a growing area of investigation, with multiple studies identifying mechanisms by which Panx1 channels can be activated.
By contrast, there remains little understanding as to how Panx1 channels are inhibited. The results of our current study provide a novel mechanism by which Panx1 channels can be inhibited, supporting a functional role for NO in controlling the activity of Panx1 channels at the plasma membrane of cells and suggesting a way to negatively regulate ATP release from cells.
Although our results indicate an inhibitory role imparted by NO on Panx1 channels through S-nitrosylation, a recent study has implicated this reactive oxygen species in Panx1 channel activation (37). In that work, it was suggested that NO generated during oxygen-glucose deprivation can activate Panx1 channels expressed in cultured hippocampal neurons. While it is possible that NO signaling may result in differential Panx1 channel regulation in different physiological contexts, it is important to point out that the aforementioned study used calcein dye leakage as a functional readout for Panx1 channel activity. Since cultured hippocampal neurons express connexin proteins, which are both permeable to calcein dye and activated by S-nitrosylation (28,30), it is possible that the dye leakage observed in this study represented activity of connexins. Moreover, it is possible that cultured hippocampal neurons express other pannexin isoforms, such as Panx2, which is highly expressed in the central nervous system (38,39). As such, other pannexin isoforms may be regulated differently by NO. In our work, we assessed S-nitrosylation and recorded whole cell currents as well as ATP release from recombinant Panx1 channels, providing direct evidence for inhibition of Panx1 by NO.
We performed cysteine mutagenesis of Panx1 to identify the specific residues required for Snitrosylation and channel inhibition. Interestingly, the two sites that we identified as critical for this inhibitory modification --C40 and C346 --were previously reported to enhance activity of Panx1 channels in mutagenesis studies (40, 41) . In that other work, serine substitution at either C40 (41) or C346 (40) produced "leaky" or constitutively active channels. Together with our results, these observations suggest that C40 and C346 may be localized to regions that are important for dynamic up-and down-regulation of Panx1 channel activity.
We noted that mutation of either C40 or C346 affected the banding pattern of Panx1 on a Western blot. It is known that Panx1 exists in three forms: a core unglycosylated species (Gly0), a high-mannose species (Gly1) and a complex glycosylated form (Gly2), each contributing to the characteristic triple banding pattern on a Western blot. Mutation of C40 or C346 resulted in a marked reduction in the Gly2 species, with the protein detected mainly as Gly0 and Gly1 forms. Since glycosylation has been implicated in trafficking of Panx1 channels to the plasma membrane, we examined the cellular localization of the cysteine mutants and found that each mutant appeared at the plasma membrane. Even though these cysteine substitutions may have affected Panx1 glycosylation status, it is important to point out that Panx1 currents and ATP release were detected for all mutant constructs, indicating that they could form functional channels at the plasma membrane. This is consistent with previous work indicating that all Panx1 Gly species can reach the plasma membrane (26). Also, a previous study identified a loss in the Gly2 species in functional, plasma membrane-localized Panx1C346S (40).
S-nitrosylation of Panx1 channels may function physiologically as a negative feedback mechanism, mediating inhibition of channel activity following their activation to prevent chronic release of ATP.
In the vasculature, endothelial cells that line the blood vessel lumen express functional Panx1 channels at the plasma membrane and multiple studies have emerged implicating these channels in ATP release (7, 11, 14, 15, 35) . Recently, it was suggested that thrombin, by activation of endothelial cell PAR-1 receptors, promotes ATP release from Panx1 channels into the extracellular compartment (14) . Our data utilizing mouse aortic endothelial cells indicates that thrombin-induced ATP release from these cells can be significantly inhibited by Snitrosylation of the channel. This novel regulatory mechanism may play an important role in controlling the extent of ATP release from the vascular endothelium and therefore modulate purinergic signaling events in the vasculature. In addition, circulating erythrocytes release ATP via Panx1 into the blood vessel lumen during conditions of low oxygen tension and membrane deformation, conditions that arise in small arterioles and capillaries (11, 15) . Released ATP activates endothelial cell P2Y receptors causing NO generation which diffuses to and relaxes adjacent smooth muscle cells (42) . It is possible that the endothelial-derived NO could also diffuse into the blood vessel lumen and S-nitrosylate erythrocyte Panx1 channels, inhibiting further ATP release and preventing excess vasodilation. Regulation of Panx1 channels by S-nitrosylation in these cells could therefore play an important role in the matching of blood flow to tissue oxygen demand. While the inhibitory effect of S-nitrosylation on Panx1 channel function was demonstrated, the mechanism by which this modification elicits its effects on the channel is not as clear. In this respect, our data indicate that S-nitrosylation has no effect on Panx1 cell membrane localization suggesting the possibility that channel activity is directly inhibited. Recent evidence has indicated that the C terminal tail may form a portion of the Panx1 channel pore (43) and that proteolytic cleavage of the C terminal tail increases channel currents by its removal from the Panx1 pore (25). It is possible that S-nitrosylation of C346 and C40 promotes a conformation that stabilizes the Cterminal:pore interaction, and thus the channel closed state. Future studies utilizing structural and biophysical techniques may reveal the precise mechanism by which Panx1 S-nitrosylation inhibits the channel. Nonetheless, our data has provided novel evidence for a post-translational mechanism inhibiting Panx1 channels at the plasma membrane. We would like to thank Daniel Schwartz (U. Conn.) for his help with the scan-x prediction method, Robert K. Nakamoto (U. Virginia) for initial help with plasmid generation, and Dr. Stefanie Gödecke (Heinrich-HeineUniversity, Düsseldorf, Germany) for advise with thrombin application to endothelial cells. Sun, J., Xin, C., Eu, J. P., Stamler, J. S., and Meissner, G. A. Biotin switch assay on primary mouse aortic endothelial cells (mAECs) treated with 100 µM GSNO ± 1 mM DTT, 50 µM DEA NONOate ± 1 mM DTT or 100 µM GSH. Ascorbate was omitted from the assay as a negative control. B. Time series showing peak Panx1 whole cell current amplitude from mAECs during application of GSNO, DTT and CBX. C. I/V curves of Panx1 currents from primary mAECs under control conditions (black trace), following application of 100 µM GSNO (red trace), 1 mM DTT (green trace) and CBX (blue trace). C. Summary data showing the percent of Panx1 current inhibition by GSNO or GSH that was reversible by DTT. D. ATP release assay from mAECs stimulated with 1U/mL mouse thrombin. Cells were pretreated with 100 µM GSNO, 50 µM DEA NONOate, 100 µM GSH or 50 µM CBX. A subset of cells was transfected with siRNA against mouse Panx1 to knockdown the endogenous protein. All data are presented as a % change in ATP release compared to control (-thrombin). Panel E insert depicts a Panx1 Western blot of untransfected and Panx1 siRNA transfected mAECs. eNOS and GAPDH were used as loading controls. n-values are indicated in brackets. **, p<0.001; *** p<0.0001.
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